In summary, the present study validates the prognostic value of BRCA1 in early-stage NSCLC and identifies XPG as a modulator of the risk of recurrence in patients with high BRCA1 mRNA levels. These findings could have important implications for the optimal use of adjuvant chemotherapy.
Address for correspondence
Rafael Rosell, MD, Catalan Institute of Oncology, Medical Oncology Service, Hospital Germans Trias i Pujol, Rafael Rosell, MD, PhD, Catalan Institute of Oncology, Medical Oncology Services, Hospital Germans Trias i Pujol, Carretera Canyet, S/N Badalona, Barcelona 08916 Spain. Fax: 34-93-497-89-50; E-Mail: firstname.lastname@example.org
Clin Lung Cancer. 2009;10(1):47-52. © 2009
Cite this: XPG mRNA Expression Levels Modulate Prognosis in Resected Non-small-cell Lung Cancer in Conjunction With BRCA1 and ERCC1 Expression - Medscape - Jan 01, 2009.